{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:11:01Z","timestamp":1790111461988,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008052","name":"Alfonso Mart\u00edn Escudero Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005977","name":"Kaiser Permanente LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116907","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:24:06Z","timestamp":1782404646000},"page":"116907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018\u20132025: A cross-sectional analysis"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-7220","authenticated-orcid":false,"given":"Guanqiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8872-7931","authenticated-orcid":false,"given":"Yiwen","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-1852","authenticated-orcid":false,"given":"Congzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":false,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-6987","authenticated-orcid":false,"given":"Ariadna","family":"Tibau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116907_bib1","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of randomised controlled trials in oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the Randomized Clinical Trial in the Era of Precision Oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(24)00152-9","article-title":"Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis","volume":"25","author":"Naci","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(19)30338-9","article-title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis","volume":"20","author":"Del Paggio","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100117","article-title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","volume":"6","author":"Gyawali","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116907_bib7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102293","article-title":"The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis","volume":"100","author":"Dabush","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116907_bib10","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116907_bib12","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/blood-2023-183089","article-title":"Design Characteristics and Risk of Bias of Pivotal Trials Supporting Approval of Hematological Drugs By FDA, 2008-2022: Cross Sectional Analysis","volume":"142","author":"Khan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116907_bib13","doi-asserted-by":"crossref","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ejca.2026.116907_bib14","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(25)00329-8","article-title":"Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejca.2026.116907_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration","volume":"110","author":"Tibau","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116907_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejca.2026.116907_bib17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1470-2045(25)00361-4","article-title":"The importance of high-quality evidence supporting cancer drug approvals","volume":"26","author":"Vokinger","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/NOR.0b013e3181db5471","article-title":"Seeking health information: what sources do your patients use?","volume":"29","author":"Cutilli","year":"2010","journal-title":"Orthop Nurs"},{"key":"10.1016\/j.ejca.2026.116907_bib20","unstructured":"US Food and Drug Administration. New Molecular Entity (NME) Drug and New Biologic Approvals. Accessed May 6, 2026. \u3008https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/new-molecular-entity-nme-drug-and-new-biologic-approvals\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib21","unstructured":"US Food\u00a0and Drug Administration. Oncology (Cancer)\/Hematologic Malignancies Approval Notifications. Accessed May 6, 2026. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib22","unstructured":"US Food\u00a0and Drug Administration. Drugs@FDA. Accessed May 6, 2026. \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaf195","article-title":"Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021","author":"Tibau","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116907_bib24","unstructured":"Current version of RoB 2 (2019). Accessed May 6, 2026. \u3008https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/current-version-of-rob-2\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib25","unstructured":"European Society for Medical Oncology (ESMO). ESMO-MCBS scorecards and evaluation forms for solid tumors and hematologic malignancies. Accessed May 6, 2026. \u3008https:\/\/www.esmo.org\/frameworks-and-tools\/esmo-mcbs\/esmo-mcbs\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.annonc.2023.06.002","article-title":"ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0","volume":"34","author":"Kiesewetter","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41571-022-00636-y","article-title":"An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?","volume":"19","author":"Cherny","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-023-00728-3","article-title":"Newly approved cancer drugs in China - innovation and clinical benefit","volume":"20","author":"Zhang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2021.03.044","article-title":"Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time","volume":"150","author":"Thomson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2685","article-title":"Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021","volume":"3","author":"Vokinger","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ejca.2026.116907_bib31","unstructured":"Archive: RoB 2.0 (2016) Cluster-randomized trials (parallel groups). Accessed May 6, 2026. \u3008https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/archive-rob-2-0-cluster-randomized-trials-2016\u3009 n.d."},{"key":"10.1016\/j.ejca.2026.116907_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116108","article-title":"Identifying informative censoring from censoring patterns across successive follow-ups","volume":"232","author":"Olivier","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2022.04.006","article-title":"FDA precedents in drug approvals: Contradiction in promoting more treatment options","volume":"169","author":"Olivier","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.008","article-title":"Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study","volume":"189","author":"Rossi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib36","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102666","article-title":"Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review","volume":"122","author":"Shachar","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116907_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25983-9","article-title":"Association between control group therapy and magnitude of clinical benefit of cancer drugs","volume":"12","author":"Molto","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2026.116907_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115357","article-title":"Guidance for discussants of randomized cancer trials at major meetings","volume":"220","author":"Eisenhauer","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib41","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116907_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116041","article-title":"Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology","volume":"230","author":"Abdihamid","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib43","article-title":"Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration","volume":"386","author":"Manyara","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116907_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113942","article-title":"Equal censoring but still informative: When the reasons for censoring differ between treatment arms","volume":"201","author":"Olivier","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116907_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2022.01.006","article-title":"Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours","volume":"164","author":"Maniar","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600688X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600688X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:14:05Z","timestamp":1787112845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600688X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"alternative-id":["S095980492600688X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116907","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018\u20132025: A cross-sectional analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116907"}}